The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy (GELUPO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02024191|
Recruitment Status : Unknown
Verified December 2013 by Ozan Yazici, Ankara Education and Research Hospital.
Recruitment status was: Recruiting
First Posted : December 31, 2013
Last Update Posted : December 31, 2013
|Condition or disease||Intervention/treatment||Phase|
|Peripheral Neuropathy||Dietary Supplement: Glutamine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer Patients. Randomized Trial|
|Study Start Date :||December 2013|
|Estimated Primary Completion Date :||January 2015|
|Estimated Study Completion Date :||June 2015|
The patient group had 3x10 gr daily glutamine during first 4 cycles of mFOLFOX6 regimen.
Dietary Supplement: Glutamine
Other Name: Resource Glutamine 3x10 gr per day
No Intervention: Observation
The group who had only mFOLFOX6 regimen, no additional intervention for neuropathy prophylaxis..
- Electromyography parameters [ Time Frame: 4 months interval ]Electromyography action potential values will be compared between two patient groups.
- Neurological signs and symptoms [ Time Frame: 4 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02024191
|Contact: Ozan Yazici, MD||+90 312 firstname.lastname@example.org|
|Contact: Nuriye Ozdemir, MD||+90 312 email@example.com|